EGFR and neoplasm: Although the presence of BRAF mutations does not contraindicate the use of anti-EGFR antibodies, patients with BRAF mutant cancer have a poor prognosis due to the relative resistance of this tumor type to chemotherapy and often receive more aggressive therapeutic regimens [7,8].